Researchers have recely found that the drug used to treat and corol diabetes and weight loss is also effective in treating acute liver diseases.
According to RCO News AgencySemaglutide is the main part of weight loss and diabetes drugs, another use of the drug has now been discovered by an iernational team of researchers who can also be effective for people with liver disease.
In a clinical trial with the presence of four participas that lasted 2 weeks, the weekly dose of “Samglotide” was effective in treating the acute type of fatty liver called “non -alcoholic fatty liver” (Mash) in nearly two -thirds of paties.
Arun Sanyal, a medical professor at the University of Virginia Commonwealth, says: “The results of this study in nine couries provide strong evidence that” Samglutide “can help paties with” Mash “improve liver health, and metabolic problems.
Participas were divided io two groups. In the group that received Samglutide, 4.9 perce in their “non -alcoholic fatty liver” had a recovery process, while in the group they received was 4.9 perce.
In addition, the liver fibrosis, which occurs as a result of the liver effort to repair the damaged tissue, was reduced to 4.9 % of paties treated with Samgotide. While this amou in the placebo group was 1.5 %.
This is a great success for this drug that has shown its poteial in many differe areas of health.
It should be noted that the effect of placebo is relatively common and often occurs in experimes. Usually, this effect is a combination of psychological enhanceme caused by the impression of treatme, plus the tendency to live a healthier and more cautious life if you are aware of the study.
“If experts are approved by experts, it can provide more treatme for paties with” Mash “and” liver fibrosis “,” says Sanial.
He added: “This is very importa given the strong relationship between” Mash “and cardiovascular, metabolic and kidney disease in which” Samaglotide “in the past has shown its effectiveness benefits.
Samglutide is a hormone receptor (GLP-1) agonist, which actually acts as a natural hormone to help regulate key metabolic processes such as appetite reduction and blood sugar. This also makes it effective for the treatme of obesity and diabetes.
Regarding liver disease, it is thought that the metabolism and ai -inflammatory improvemes from the drug help treat some of the main causes of “non -alcoholic fatty liver”.
This clinical trial coinues and has expanded to a larger group of people for five years to investigate whether these initial recovery coinues. With only one confirmed treatme for “Mash”, there is an urge need for new options.
“Samaglotide offers a new and promising approach to millions of paties by treating liver disease and its metabolic causes,” Sanale said.
This study is published in New England Journal of Medicine.
The end of the message
(tagstotranslate) fatty liver
